Educational use only. Check doses against the product monograph and local protocols.

RSI drugs

in review 3 min read Updated 2026-10-29
RSI drugs

In the critically ill: always pair a sedative-hypnotic with a neuromuscular blocker (SCCM 2023, strong). Induction agents don’t differ in mortality or peri-intubation hypotension, so choose on haemodynamics and cut the dose in shock. Rocuronium or succinylcholine are equal choices; sux is out with hyperkalaemia risk. Cisatracurium is the ARDS paralytic.

induction agents

agentdose (IV)haemodynamicsnotes
etomidate0.2–0.4 mg/kg (usual 0.3); 0.15–0.2 in elderlyfew cardiovascular effects, but no less hypotension than other agents in trialssuppresses cortisol and aldosterone (can be prolonged). SCCM suggests against giving steroids just to cover etomidate; label advises caution in sepsis and considering cortisol under severe stress
ketamine1–2 mg/kg (lower in shock)sympathomimetic; may still drop BP in catecholamine-depleted shock bronchodilator; preserves drive
propofolreduce sharply in shockvasodilation, ↓ contractility → most hypotension→ ICU sedatives
midazolam—slow onset, hypotensionnot a good induction agent
  • no difference between etomidate and other agents for mortality, hypotension or vasopressor use (SCCM 2023, conditional, moderate)
  • hypotension after intubation is common whatever the drug: have a pressor running or ready → mechanical ventilation

neuromuscular blockers

agentdoseonset / durationavoid / caution
succinylcholine (depolarising)1–1.5 mg/kg (label 0.6, range 0.3–1.1)~1 min / 4–6 minhyperkalaemia; after the acute phase (peak 7–10 days) of burns, major trauma, denervation, upper motor neuron injury; neuromuscular disease (rhabdomyolysis); malignant hyperthermia susceptibility
rocuronium (aminosteroid)1–1.2 mg/kg for RSI60–90 s / 30–60+ min (longer in obesity, hepatic failure)anaphylaxis (rare); prolonged paralysis means sedation must continue
cisatracurium (benzylisoquinoline)bolus, then infusion ~1–3 mcg/kg/min titrated to train-of-fourslower onset / short; organ-independent elimination (Hofmann)preferred ARDS infusion (used in the largest trials)
  • sux vs roc (SCCM 2023, conditional): either when sux isn’t contraindicated. First-pass success was similar in the ICU trial (82% vs 84%); the larger non-inferiority trial was inconclusive, and success depends on giving enough rocuronium (≥1–1.2 mg/kg)
  • after rocuronium the patient stays paralysed for an hour or more: start sedation and analgesia immediately. Most reports of awareness under paralysis followed longer-acting NMBAs
  • ARDS: early severe ARDS only (already deeply sedated, or dyssynchrony despite sedation), boluses or ≤48 h infusion; ESICM recommends against routine continuous infusion → ards
  • long-term ICU NMBA infusions → prolonged weakness. Monitor with a nerve stimulator and stop daily where possible

adverse effects

  • succinylcholine: K⁺ rise, life-threatening in the at-risk groups above; bradycardia (repeat doses, children); fasciculations, myalgia; ↑ intraocular pressure
  • etomidate: myoclonus, adrenal suppression, nausea
  • all NMBAs: awareness without sedation; ICU-acquired weakness with prolonged infusions (especially with steroids) → ICU-acquired weakness

Prepared 2026-10-29. Not yet verified — check every number against the sources.

Key references

+4 more sources

Suggest a correction RSI drugs